In breast cancer cell lines, PARP inhibitor (Olaparib) can significantly decrease the proportion of BCSCs with CD44+/CD24−/low/ESA+ cell surface marker, indicating the potential activity of PARP inhibitor in anticancer stem cells (92) (Figure 2, Table 2). Here, CD24 is linked to breast cancer.